Introduction
Epileptic encephalopathies due to mutations in the DNM1 gene are a new severe childhood neurologic disorder typically characterized by intractable epilepsy beginning with infantile spasms, developmental delay and movement disorder [1] . The DNM1 gene (MIM 602377, 9q34.11, NM_004408.3, 22 exons, 864 amino acids) encodes dynamin 1, a GTPase which plays a crucial role in the catalysis of clathrin-mediated endocytosis and synaptic vesicle recycling. DNM1 is organized into five domains: a) a G domain that binds and hydrolyzes GTP; b) a middle domain that is involved in oligomerization; c) a pleckstrin homology domain; d) a GTPase effector domain, and e) a proline-rich domain. During receptor-mediated endocytosis, dynamin molecules assemble into tetramers and form helical polymers at the necks of budding vesicles. Upon GTP hydrolysis, the DNM1 helices undergo a conformational change that leads to membrane constriction and scission of the vesicles from the membrane. Defective recycling causes depletion of GABA-containing synaptic vesicles resulting in decreased inhibitory neurotransmission in mice [2] . To date, 27 patients from 26 families with epileptic encephalopathy carrying DNM1 mutations have been described in the literature (Suppl .  Table) . Seventeen different de novo missense mutations with autosomal dominant inheritance have been reported so far. Eight of the 27 patients had the recurrent p.Arg237Trp mutation (Suppl .  Table) .
Here we describe a case of a patient with an encephalopathy due to a novel de novo in frame-insertion in the DNM1 gene.
Case description
We report a girl from the 3rd low-risk pregnancy, born in the 40th week of gestation (birth weight 4030 g, birth length 53 cm, Apgar score 5/8/10) requiring a short-term ventilation support after the birth. Multifocal myoclonus and tonic seizures were present since the 1st day of life treated with phenobarbital. EEG was without epileptiform discharges. Myoclonus persisted and infantile spasms manifested from the 6th week of life. The EEG showed an abnormal activity of background, irregular sharp waves and spike and waves complexes followed by attenuation. Next treatment started at the 2nd month of life and included valproate, levetiracetam, and clobazam gradually. The evolution of EEG changes is shown in Fig. 1A and B. Later, at 10 months of age, nonepileptic myoclonic jerks were dominant, both isolated and generalized, shown on several EEG recordings (Fig. 1C) . Hypomyelinating leukoencephalopathy and ventriculomegaly were visible since the 6th month of age on the MRI. At the age of 4 years, her brain myelination status matched to a healthy child aged 10 months (Fig. 2) .
Currently, at the age of 5 years, she suffers from profound psychomotor developmental delay, without verbal expression, unable to roll over or sit alone. Due to problems with feeding a percutaneous endoscopic gastrostomy was inserted. Sever hypotonic syndrome with hyporeflexia remained unchanged since birth. Generalized myoclonic jerks in series are present along with nocturnal tonic seizures.
With the aim of identification of the etiology of the disease, we have performed a selective metabolic screening including cerebrospinal fluid evaluation, TORCH screening, and DNA analysis to exclude spinal muscular atrophy type I; all with negative results. Arylsulphatase-A enzyme testing was negative, and dermal fibroblast examination showed normal mitochondrial enzyme activities.
Whole exome sequencing of the patient's DNA revealed the presence of an in-frame insertion c.1089_1090insCTTCCA in exon 8 of the DNM1 gene (NM_004408.3) in the heterozygous state. This mutation should cause an insertion of leucine and proline between Asn363 and Arg364 (p.Asn363_Arg364insLeuPro) in the middle domain of the protein. Parental analysis of exome 8 revealed the de novo nature of the patient's mutation (confirmed by paternity testing). Variant c.1089_ 1090insCTTCCA was not described in the literature and is not included in public population databases (dbSNP150, EVS, ExAC).
Discussion
We have found a novel de novo variant in the DNM1 gene in a girl with the infantile epileptic encephalopathy. Since the DNM1 gene came as a candidate from a study of de novo mutations in large cohorts of epileptic patients [3] , together 28 patients from 27 families with 18 different pathogenic variants (including our patient) have been described (Suppl. Fig.) . All pathogenic variants found in the DNM1 patients so far were missense mutations created de novo. Our patient has a novel DNM1 variant, the first in-frame insertion identified until now in the DMN1 gene. The DNM1 gene has a high gene constraint Z-score = 5.97 and maximal Fig. 1 . Electroencephalogram of the proband on various occasions. A. EEG at the age of 2 months: abnormal activity of background, irregular sharp waves (dashed frame) and spike and waves complexes (solid frame) followed by attenuation, predominant over the right hemisphere; B. EEG at the age of 6 months: interictal EEG complexes of sharp and slow waves (frame), abnormal background, and rightside asymmetry; C. Ictal EEG during non-epileptic general myoclonic jerks at the age of 2 years (frame). Fig. 2 . MRI of the proband at the age of 6 weeks, 6 months, 27 months, and 4 years respectively. A. MRI (T2W TSE NEO) at age of 6 weeks, myelination of white matter corresponds to the 1st month, leukoencephalopathy in frontal and occipital areas without acute changes; B. MRI (T2W) at the age of 6 months, white matter myelination is slightly delayed À corresponds to the 2nd-3rd month of life; C. MRI (T2W) at the age of 27 months, myelination corresponds to the 6th-7th month of life; D. MRI (T2W) at the age of 4 years: white matter myelination significantly delayed, corresponds to the 10th month of life, periventricular leukoencephalopathy is discernible (arrow). Ventriculomegaly was present from 6 months (B-D).
loss-of-function intolerance probability score pLI = 1.0, indicating extremely high intolerance to both missense and loss-of-function variants [4] . Together with its de novo nature and the specific phenotype matching with other DNM1 patients, we consider this variant most likely pathogenic.
Our patient has one of the most severe forms of DNM1 encephalopathy when compared to other reported patients. In the recent Spiczak study [1] only one in 21 patients had delayed myelination on MRI. The location of his mutation was in the middle domain of the dynamin 1. This could be attributed to the in-frame insertion that might have a stronger impact on the protein structure than missense mutations. The previously reported mutations were found mainly in the GTPase domain (Suppl. Fig.) ; six mutations, including the one found in our patient, are located in the middle domain. Comparing the clinical course of reported cases, patients with middle domain DNM1 mutations seem to have a more atypical phenotype. The symptom of epilepsy is variable and in two patients, including ours, we found a nonepileptic myoclonus and delayed myelination on MRI. Moreover, the severity of features can be influenced by other genetic or environmental factors [1, 3] .
In our case, hypomyelination was an important MRI feature since the first year of life of the patient, while it was reported in only two other DNM1 patients [1] .
In conclusion, in conjunction with prior reports (Suppl . Table) we suggest that mutations in the DNM1 gene cause a severe form of epileptic encephalopathy including the serious global developmental delay of variable severity, hypotonia, non-epileptic myoclonus and possible serious changes on MRI. 
